The Clinical Implication of Blood Product Transfusion on Morbidity and Mortality of XXXX .

@entity1 @entity715 @entity1755
BACKGROUND: Transfusion of blood products occurs frequently in @entity1755 surgery (rAAA). The aim of this study is to establish the impact of packed red blood cell (PRBC), fresh frozen plasma (FFP), and platelet (PLT) transfusion on the 30-day mortality and morbidity ( @entity715 versus non @entity715 ) of rAAAs. METHODS: A retrospective study of 90 consecutive rAAAs from November 2007 to June 2015 was conducted. Multivariable regression models were produced to determine blood products associated with 30-day morbidity and mortality post-rAAA. RESULTS: The overall mortality was 14.6%. At multivariable analyses, transfusion with FFP (>3 units) was independently associated with an increased risk of mortality (odds ratio [OR]: 11.27, 95% confidence interval [CI]: 1.13-96.72, P = .027). The overall morbidity was 26.8%, and subgroup analysis ( @entity715 ) demonstrated transfusion of PLTs (>1 pool) to be independently associated with @entity715 events (OR: 4.3, 95% CI: 1.37-13.6, P = .012). @entity715 events were responsible for 50% (n = 11 of 22) of all morbidities and mortalities (n = 6 of 12). CONCLUSION: Transfusion of FFP and PLTs may be associated with an increased risk of postoperative morbidity and mortality. The use of these blood components should be considered in the context of the @entity1 's clinical and laboratory data as opposed to a fixed ratio to PRBCs. This may result in the reduction in @entity715 emerging in rAAA cohort.
